pancreatic cancer action network logo donate now
Join our mailing list
En Español  
Search  
 
Share this Webpage!   Adjust Text Size:  P P P
Scientific Strategy
 

Viewpoints / Position Papers

Study Documents Significant Underuse of Surgical Resections

Pancreatectomy, the surgical removal of all or part of the pancreas, offers the best chance of long-term control of all types of pancreatic cancer. However, the use of surgery is significantly underused, even among eligible candidates, according to a published national study.*

Led by Karl Y. Bilimoria, MD, a surgeon at Northwestern University in Chicago, the research team analyzed data on 9,559 patients with “potentially resectable” early stage cancers of the pancreas treated between 1995 and 2004. The goal of the study was to evaluate the use of surgery and to find out why physicians chose not to use it as a treatment option in some case.

Surgery was not utilized as a treatment option in 71 percent of cases: the vast majority of the patients. Of these, close to 20 percent were considered too old, too ill or refused the operation. As many as 38 percent were not offered the surgical option, and no identifiable reason was cited for an additional 14 percent of the patients.

Patients treated at centers with a high average annual volume of pancreatic cancer cases and at academic institutions were more likely to undergo surgery than those at low volume centers and community hospitals. Surgical resections were significantly more likely at National Comprehensive Cancer Network hospitals and National Cancer Institute-designated cancer centers. This was most likely is due to clincians’ greater access to the latest diagnostic and surgical approaches, multidisciplinary support, and resources.

For questions about this study, or to find a high-volume center near you, please contact a PALS Associate at 877-272-6226 or email pals@pancan.org.

*Bilimoria, KY, et. al., National Failure to Operate on Early Stage Pancreatic Cancer, Annals of Surgery 2007;246,2:173-180.

Click here to access PubMed and the full-text of this article.



 
  

1500 Rosecrans Avenue, Suite 200, Manhattan Beach, CA 90266
Toll Free: 877-272-6226 | Phone: 310-725-0025 | Fax: 310-725-0029
  Share This Site
Donate Now | Press | Contact Us
Site Map | Privacy Policy | Job Listings
Site Problems | Join Our Mailing List | Newsletter Survey

Our 9th Consecutive Year.

Honors the Pancreatic Cancer Action Network as
ranking in the top ten of outstanding charities.

© 2013 Pancreatic Cancer Action Network
PANCAN®, PURPLESTRIDE®, PURPLERIDE® PURPLEBOWL®, TEAMHOPE® and
PANCREATIC CANCER ACTION NETWORK® are registered trademarks.